Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Daiichi Sankyo
Colorcon
Mallinckrodt
Johnson and Johnson
Fuji
Citi
Merck

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FIRAZYR

« Back to Dashboard

Clinical Trials for Firazyr

Trial ID Title Status Sponsor Phase Summary
NCT00912093 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed Shire Phase 3 This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
NCT00997204 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed Jerini AG Phase 3 This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
NCT00997204 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed Shire Phase 3 This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
NCT01386658 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Active, not recruiting Shire Phase 3 HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with Hereditary Angioedema (HAE) during an initial acute attack.
NCT01457430 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed Shire Human Genetic Therapies, Inc. Phase 4 The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.
NCT01457430 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed Massachusetts General Hospital Phase 4 The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.
NCT01574248 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated Vanderbilt University Phase 0 Individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ACE) inhibitors to treat their disease. However, the use of ACE inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. This study will evaluate the effectiveness of the drug HOE-140 at decreasing symptoms of angioedema in people taking ACE inhibitors who develop the condition.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Firazyr

Condition Name

Condition Name for Firazyr
Intervention Trials
Hereditary Angioedema 3
Hereditary Angioedema (HAE) 2
Angiotensin Converting Enzyme Inhibitor Induced Angioedema 1
ACE Inhibitor-associated Angioedema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Firazyr
Intervention Trials
Angioedema 7
Angioedemas, Hereditary 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Firazyr

Trials by Country

Trials by Country for Firazyr
Location Trials
United States 63
Canada 6
Australia 5
France 5
Israel 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Firazyr
Location Trials
California 6
Pennsylvania 4
Maryland 4
Texas 4
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Firazyr

Clinical Trial Phase

Clinical Trial Phase for Firazyr
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Firazyr
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Firazyr

Sponsor Name

Sponsor Name for Firazyr
Sponsor Trials
Shire 5
Jerini AG 1
PPD 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Firazyr
Sponsor Trials
Industry 8
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Medtronic
McKinsey
Dow
QuintilesIMS
US Department of Justice
Boehringer Ingelheim
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.